1
|
Xu Z, Michel KA, Walker CM, Harlan CJ, Martinez GV, Gordon JW, Chen HY, Vigneron DB, Bankson JA. Model-constrained reconstruction accelerated with Fourier-based undersampling for hyperpolarized [1- 13 C] pyruvate imaging. Magn Reson Med 2023; 89:1481-1495. [PMID: 36468638 PMCID: PMC9892212 DOI: 10.1002/mrm.29551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 11/14/2022] [Accepted: 11/15/2022] [Indexed: 12/12/2022]
Abstract
PURPOSE Model-constrained reconstruction with Fourier-based undersampling (MoReFUn) is introduced to accelerate the acquisition of dynamic MRI using hyperpolarized [1-13 C]-pyruvate. METHODS The MoReFUn method resolves spatial aliasing using constraints introduced by a pharmacokinetic model that describes the signal evolution of both pyruvate and lactate. Acceleration was evaluated on three single-channel data sets: a numerical digital phantom that is used to validate the accuracy of reconstruction and model parameter restoration under various SNR and undersampling ratios, prospectively and retrospectively sampled data of an in vitro dynamic multispectral phantom, and retrospectively undersampled imaging data from a prostate cancer patient to test the fidelity of reconstructed metabolite time series. RESULTS All three data sets showed successful reconstruction using MoReFUn. In simulation and retrospective phantom data, the restored time series of pyruvate and lactate maintained the image details, and the mean square residual error of the accelerated reconstruction increased only slightly (< 10%) at a reduction factor up to 8. In prostate data, the quantitative estimation of the conversion-rate constant of pyruvate to lactate was achieved with high accuracy of less than 10% error at a reduction factor of 2 compared with the conversion rate derived from unaccelerated data. CONCLUSION The MoReFUn technique can be used as an effective and reliable imaging acceleration method for metabolic imaging using hyperpolarized [1-13 C]-pyruvate.
Collapse
Affiliation(s)
- Zhan Xu
- Department of Imaging Physics, The University of Texas-MD Anderson Cancer Center, Houston, TX
| | - Keith A. Michel
- Department of Imaging Physics, The University of Texas-MD Anderson Cancer Center, Houston, TX
| | - Christopher M. Walker
- Department of Imaging Physics, The University of Texas-MD Anderson Cancer Center, Houston, TX
| | - Collin J. Harlan
- Department of Imaging Physics, The University of Texas-MD Anderson Cancer Center, Houston, TX
- The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX
| | - Gary V. Martinez
- Department of Imaging Physics, The University of Texas-MD Anderson Cancer Center, Houston, TX
| | - Jeremy W. Gordon
- Department of Radiology & Biomedical Imaging, University of California San Francisco, San Francisco, CA
| | - Hsin-Yu Chen
- Department of Radiology & Biomedical Imaging, University of California San Francisco, San Francisco, CA
| | - Daniel B. Vigneron
- Department of Radiology & Biomedical Imaging, University of California San Francisco, San Francisco, CA
| | - James A. Bankson
- Department of Imaging Physics, The University of Texas-MD Anderson Cancer Center, Houston, TX
- The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX
| |
Collapse
|
2
|
Sahin SI, Ji X, Agarwal S, Sinha A, Mali I, Gordon JW, Mattingly M, Subramaniam S, Kurhanewicz J, Larson PEZ, Sriram R. Metabolite-Specific Echo Planar Imaging for Preclinical Studies with Hyperpolarized 13C-Pyruvate MRI. Tomography 2023; 9:736-749. [PMID: 37104130 PMCID: PMC10143874 DOI: 10.3390/tomography9020059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Revised: 03/17/2023] [Accepted: 03/19/2023] [Indexed: 03/29/2023] Open
Abstract
Metabolite-specific echo-planar imaging (EPI) sequences with spectral–spatial (spsp) excitation are commonly used in clinical hyperpolarized [1-13C]pyruvate studies because of their speed, efficiency, and flexibility. In contrast, preclinical systems typically rely on slower spectroscopic methods, such as chemical shift imaging (CSI). In this study, a 2D spspEPI sequence was developed for use on a preclinical 3T Bruker system and tested on in vivo mice experiments with patient-derived xenograft renal cell carcinoma (RCC) or prostate cancer tissues implanted in the kidney or liver. Compared to spspEPI sequences, CSI were found to have a broader point spread function via simulations and exhibited signal bleeding between vasculature and tumors in vivo. Parameters for the spspEPI sequence were optimized using simulations and verified with in vivo data. The expected lactate SNR and pharmacokinetic modeling accuracy increased with lower pyruvate flip angles (less than 15°), intermediate lactate flip angles (25° to 40°), and temporal resolution of 3 s. Overall SNR was also higher with coarser spatial resolution (4 mm isotropic vs. 2 mm isotropic). Pharmacokinetic modelling used to fit kPL maps showed results consistent with the previous literature and across different sequences and tumor xenografts. This work describes and justifies the pulse design and parameter choices for preclinical spspEPI hyperpolarized 13C-pyruvate studies and shows superior image quality to CSI.
Collapse
Affiliation(s)
- Sule I. Sahin
- UC Berkeley—UCSF Graduate Program in Bioengineering, Berkeley, CA 94720, USA
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94016, USA
| | - Xiao Ji
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94016, USA
| | - Shubhangi Agarwal
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94016, USA
| | - Avantika Sinha
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94016, USA
| | - Ivina Mali
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94016, USA
| | - Jeremy W. Gordon
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94016, USA
| | | | - Sukumar Subramaniam
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94016, USA
| | - John Kurhanewicz
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94016, USA
| | - Peder E. Z. Larson
- UC Berkeley—UCSF Graduate Program in Bioengineering, Berkeley, CA 94720, USA
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94016, USA
- Correspondence: (P.E.Z.L.); (R.S.)
| | - Renuka Sriram
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94016, USA
- Correspondence: (P.E.Z.L.); (R.S.)
| |
Collapse
|
3
|
Salzillo TC, Mawoneke V, Weygand J, Shetty A, Gumin J, Zacharias NM, Gammon ST, Piwnica-Worms D, Fuller GN, Logothetis CJ, Lang FF, Bhattacharya PK. Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance. Cells 2021; 10:cells10102621. [PMID: 34685601 PMCID: PMC8534002 DOI: 10.3390/cells10102621] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Revised: 09/20/2021] [Accepted: 09/23/2021] [Indexed: 12/23/2022] Open
Abstract
Rapid diagnosis and therapeutic monitoring of aggressive diseases such as glioblastoma can improve patient survival by providing physicians the time to optimally deliver treatment. This research tested whether metabolic imaging with hyperpolarized MRI could detect changes in tumor progression faster than conventional anatomic MRI in patient-derived glioblastoma murine models. To capture the dynamic nature of cancer metabolism, hyperpolarized MRI, NMR spectroscopy, and immunohistochemistry were performed at several time-points during tumor development, regression, and recurrence. Hyperpolarized MRI detected significant changes of metabolism throughout tumor progression whereas conventional MRI was less sensitive. This was accompanied by aberrations in amino acid and phospholipid lipid metabolism and MCT1 expression. Hyperpolarized MRI can help address clinical challenges such as identifying malignant disease prior to aggressive growth, differentiating pseudoprogression from true progression, and predicting relapse. The individual evolution of these metabolic assays as well as their correlations with one another provides context for further academic research.
Collapse
Affiliation(s)
- Travis C. Salzillo
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; (T.C.S.); (V.M.); (A.S.); (S.T.G.); (D.P.-W.)
| | - Vimbai Mawoneke
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; (T.C.S.); (V.M.); (A.S.); (S.T.G.); (D.P.-W.)
| | - Joseph Weygand
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA;
| | - Akaanksh Shetty
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; (T.C.S.); (V.M.); (A.S.); (S.T.G.); (D.P.-W.)
| | - Joy Gumin
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; (J.G.); (F.F.L.)
| | - Niki M. Zacharias
- Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA;
| | - Seth T. Gammon
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; (T.C.S.); (V.M.); (A.S.); (S.T.G.); (D.P.-W.)
| | - David Piwnica-Worms
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; (T.C.S.); (V.M.); (A.S.); (S.T.G.); (D.P.-W.)
| | - Gregory N. Fuller
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA;
| | - Christopher J. Logothetis
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA;
| | - Frederick F. Lang
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; (J.G.); (F.F.L.)
| | - Pratip K. Bhattacharya
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; (T.C.S.); (V.M.); (A.S.); (S.T.G.); (D.P.-W.)
- Correspondence: ; Tel.: +1-713-454-9887
| |
Collapse
|